Lybalvi

Active Ingredient(s): Olanzapine + Samidorphan L-malate
FDA Approved: * May 28, 2021
Pharm Company: * ALKERMES INC
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lybalvi Overview

Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder.[1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.[1][2][3] It was approved for medical use in the United States in May 2021.[1][4] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0...

Read more Lybalvi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olanzapine/samidorphan

Recent Lybalvi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Olanzapine + Samidorphan L-malate
  • Tablet: 10mg + 10mg, 15mg + 10mg, 20mg + 10mg, 5mg + 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lybalvi: (4 results)

Sorted by National Drug Code
  • 65757-651 Lybalvi Oral Tablet, Film Coated by Alkermes, Inc.
  • 65757-652 Lybalvi Oral Tablet, Film Coated by Alkermes, Inc.
  • 65757-653 Lybalvi Oral Tablet, Film Coated by Alkermes, Inc.
  • 65757-654 Lybalvi Oral Tablet, Film Coated by Alkermes, Inc.

Drugs with one or more similar ingredients: (7 results)